Table 1 National Cancer Institute TMA—comparison of tumors expressing high and low levels of JAG1 mRNA and protein
From: High-level JAG1 mRNA and protein predict poor outcome in breast cancer
n | 10-year survival rate (95% CI) | Median survival (95% CI) | P | |
|---|---|---|---|---|
JAG1 mRNA | ||||
Low | 104 | 47% (36–57) | 100 months (77–139) | <0.001 |
High | 23 | 16% (4–34) | 43 months (12–71) | |
JAG1 protein | ||||
Low | 88 | 48% (36–59) | 108 months (76–155) | 0.03 |
High | 39 | 26% (13–41) | 63 months (34–80) | |
JAG1 mRNA/protein | ||||
Low/low | 74 | 53% (40–64) | 131 months (85–189) | 0.055a |
Low/high | 30 | 31% (15–49) | 77 months (34–83) | <0.0001b |
High/low | 14 | 19% (3–45) | 43 months (19–102) | |
High/high | 9 | 11% (0–39) | 23 months (11–71) | |
